Concise Prescribing Info
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Cutaneous larva migrans 25 mg/kg twice daily for 2 days, repeat after 2 days if needed. Max: 3 g/day. Strongyloidiasis 25 mg/kg twice daily for 2-3 days, when infection is disseminated, treat for at least 5 days. Max: 3 g/day. Dracunculiasis 25-50 mg/kg twice daily. Massive infection: A further dose of 50 mg/kg may be given after 5-8 days. Max: 3 g/day. Ascariasis; Trichostrongyliasis; Trichuriasis Trichinosis; Toxocariasis 25 mg/kg twice daily. Max: 3 g/day. Duration: 2 days (ascariasis, trichostrongyliasis and trichuriasis), 2-4 days (trichinosis), 5-7 days (toxocariasis).
Dosage Details
Cutaneous larva migrans
Adult: 25 mg/kg bid for 2 days repeated after 2 days if required. Max: 3 g/day. Alternatively, 10-15% oral suspension may be used topically.

Adult: 25 mg/kg bid for 2-3 days or 50 mg/kg as single dose, when infection is disseminated treament for at least 5 days may be necessary. Max: 3 g/day.

Adult: 25 mg/kg bid for 2-4 successive days. Max: 3 g/day.

Adult: 25 mg/kg bid for 5-7 days. Max: 3 g/day.

Adult: 25-50 mg/kg bid for one day; in massive infection, a further dose of 50 mg/kg may be given after 5-8 days. Max: 3 g/day.

Ascariasis, Trichostrongyliasis, Trichuriasis
Adult: 25 mg/kg bid for 2 consecutive days. Max: 3 g/day.
Renal Impairment
Use with caution.
Hepatic Impairment
Use with caution.
Mixed worm infections involving Ascaris lumbricoides. Prophylactic treatment for enterobiasis infection.
Special Precautions
Renal or hepatic impairment, malnutrition or anaemia, impairs ability to drive or operate machinery.
Adverse Reactions
Dizziness; GI disturbances; pruritus, skin rashes; drowsiness, headache, fatigue, drying of mucous membrane; hyperglycaemia, visual disturbances; leucopaenia; tinnitus; hepatic effects; enuresis; crystalluria; bradycardia; hypotension. Transient increase in liver test.
Potentially Fatal: Fatal Stevens-Johnson syndrome, erythema multiforme. Toxic epidermal necrolysis, liver damage.
Transient visual disturbances and psychic alterations. There is no specific antidote. Emesis should be induced or gastric lavage be performed carefully. Treatment is symptomatic and supportive.
Drug Interactions
Concurrent use inhibits metabolism of theophylline and caffeine. Possible increase in anticoagulant effect with coumarins.
Description: Tiabendazole, a benzimidazole derivative, has activity against most nematode worms, larval stages and ova. Its mechanism is uncertain but may inhibit fumarate-reductase system of worms, hence interfering with their source of energy. It also has some antifungal activity.
Absorption: Rapidly absorbed from GI tract and skin; peak plasma concentrations: 1-2 hr.
Metabolism: Extensively hepatic metabolised.
Excretion: Excreted in urine (90%) and faeces (5%)
Store 15-30°C.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Tiabendazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in